I found this post on another board, and found it interesting, though I don't know exactly what to make of it.
"Ed Vreeland wrote:
I had the pleasure of working directly for Sunil at the Bayer Company for Aproxx 8 years. He is a solid, capable, and personable manager of not just people including both direct reports but major projects. I really believe that he works better under great pressure!
He is a true visionary, he does not only think within the operations of his company, but outside the box if you will. This is all done with great taste and on a world perspective.
Sunil is both a man of honor and respect. While working for him I learned many things. To him I owe any and all success I have had in business."
Could it be that we are actually in better hands than many of us think? Does anyone think that working as a manager at a big Pharma necessarily makes for a good entrepreneur? At the point where Titan is at now, what move should be made next? Where should the emphasis be? What is Titan's mission statement NOW? Will Titan ever switch into HIGH gear producing product at a much more accelerated pace?
Mr. Bhonsle has served as our Executive Vice President and Chief Operating Officer since September 1995 and has been a Director of Titan Pharmaceuticals since February 2004. Prior to joining Titan, Mr. Bhonsle served in various positions at Bayer Corporation from July 1975 until April 1995 including most recently as Vice President and General Manager-Plasma Supply. Mr. Bhonsle holds an M.B.A. from the University of California at Berkeley and a B.Tech. in chemical engineering from the Indian Institute of Technology.
Thanks for sharing this.
Assuming this is an honest appraisal, which I have no reason to suspect it's not:
1) "Sunil is both a man of honor and respect." is the best part of Vreeland's comments.
2) Few can be exceptional in all facets of their job, so I hope Sunil's deficiiencies are picked up by Rubin, Beebe, Crowley, the search firms and now, by Braeburn Pharmaceuticals.
3) It all boils to Probuphine's approval and eventual acceptance in the market for opiod treatment.